id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S15201 R62352 |
Cohen (Valproate) (Mixed indications) (Controls unexposed, NOS), 2023 | Orofacial clefts | 1st trimester | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes | 3.21 [1.73;5.96] | -/2,031 -/4,866,362 | - | 2,031 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10174 R46500 |
Blotière (Valproate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 | Oro-facial clefts | 1st trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
4.95 [1.39;17.58] C excluded (control group) |
6/913 4/2,997 | 10 | 913 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10051 R46495 |
Blotière (Valproate) (Controls unexposed NOS) (Mixed indications), 2019 | Oro-facial clefts | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 4.40 [1.97;9.83] C | 6/913 2,815/1,875,733 | 2,821 | 913 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9359 R32737 |
Tomson (Valproate), 2018 | Cleft lip or palate | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 3.65 [0.91;14.63] C | 6/1,381 3/2,514 | 9 | 1,381 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9333 R32559 |
Campbell (Valproate) (Controls exposed to Lamotrigine, sick), 2014 | Facial cleft | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 11.29 [2.54;50.12] | 13/1,220 2/2,098 | 15 | 1,220 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9325 R32517 |
Veiby (Valproate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 | Orofacial clefts | throughout pregnancy | population based cohort retrospective | exposed to other treatment, sick | Adjustment: No | 0.83 [0.03;20.52] C | 0/333 1/833 | 1 | 333 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9309 R32425 |
Källén (Valproate) (Controls exposed to Lamotrigine, sick) (Indications NOS), 2013 | Orofacial cleft | early pregnancy | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
1.95 [0.52;7.29] C excluded (control group) |
5/697 4/1,084 | 9 | 697 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9310 R32433 |
Källén (Valproate) (Controls unexposed, NOS) (Indications NOS), 2013 | Orofacial cleft | early pregnancy | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes | 3.33 [1.08;7.78] | 5/697 2,756/1,575,847 | 2,761 | 697 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10231 R37484 |
Hernández-Díaz (Valproate) (Controls exposed to Lamotrigine, sick), 2012 | Oral clefts | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No Controls: mixed indications | 2.79 [0.81;9.57] C | 4/323 7/1,562 | 11 | 323 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 7 studies | 3.67 [2.51;5.38] | 5,618 | 6,898 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Valproate) (Mixed indications) (Controls unexposed, NOS; 2: Valproate) (Controls unexposed NOS) (Mixed indications; 3: Valproate; 4: Valproate) (Controls exposed to Lamotrigine, sick; 5: Valproate) (Controls exposed to Lamotrigine, sick) (Mixed indications; 6: Valproate) (Controls unexposed, NOS) (Indications NOS; 7: Valproate) (Controls exposed to Lamotrigine, sick;
Asymetry test p-value = 0.9446 (by Egger's regression)
slope=1.3294 (0.4165); intercept=-0.0593 (0.8111); t=0.0731; p=0.9446
excluded 9309, 10174